More than one Activase® dosing regimen can be used for Acute Myocardial Infarction (AMI)

Two Activase dosing regimens have been studied in patients experiencing AMI. However, the comparative efficacy of these two regimens has not been evaluated. 6

Read about the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Trial: An international study of accelerated infusion in AMI patients

  • Accelerated infusion of Activase was studied in the GUSTO trial that randomized 41,021 patients with AMI to four thrombolytic regimens.
  • Entry criteria for this international, multi-center trial included onset of chest pain within 6 hours of treatment and ST-segment elevation of ECG.

Consider the results for the primary endpoint of the study, 30-day mortality, as well as secondary endpoints:

Event Accelerated Activase SK (IV)a P valueb SK (SQ)a P valueb
30-day mortality 6.3% 7.3% 0.003 7.3% 0.007
30-day mortality or nonfatal stroke 7.2% 8.2% 0.006 8.0% 0.036
24-hour mortality 2.4% 2.9% 0.009 2.8% 0.029
Any stroke 1.6% 1.4% 0.32 1.2% 0.03
Intracerebral hemorrhage 0.7% 0.6% 0.22 0.5% 0.02

a IV and SQ refer to heparin route of administration. All patients also received chewable aspirin and heparin.
Two-tailed P value is for comparison of Accelerated Activase to the respective SK control arm.

IV, intravenous; SK, streptokinase; SQ, subcutaneous.

NEXT: AMI Dosing and Administration Guidelines >